Telmisartan in incipient and overt diabetic renal disease

Journal of Nephrology

Volumn 24, Issue 3, 2011, Pages 263-273

  Schmieder, Roland E ^a   Bakris, George ^b   Weir, Matthew R ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin receptor blocker; Diabetic nephropathy; Diabetic renal disease; Telmisartan

Indexed keywords

ALBUMIN; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; ENALAPRIL; GLUCOSE; LOSARTAN; NIFEDIPINE; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ALBUMINURIA; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HEART FUNCTION; HEART PROTECTION; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LIPOPHILICITY; MACROALBUMINURIA; MICROALBUMINURIA; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROTEINURIA; PUBLIC HEALTH; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR DISEASE;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; TREATMENT OUTCOME;

EID: 79955935382     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.6416     Document Type: Article

References (72)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39 (Suppl 1):S1-S266. Available at: http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm. Accessed January 26, 2009.
2. US Renal Data System. 2008 ADR/Atlas. Vol. 2. Atlas of endstage renal disease in the United States. Available at: http://www.usrds.org/atlas.htm. Accessed January 26, 2009.
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
4. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225-232.
5. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
6. De Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med. 2004;164:2459-2464.
7. ®: cardiovascular outcome in patients at high cardiovascular risk and chronic kidney disease (CKD). Program and abstracts from Hypertension 2008: 18th scientific meeting of the European Society of Hypertension/22nd scientific meeting of the International Society of Hypertension, Berlin, Germany, June 14-19, 2008 [abstract OS31/THU/02].
8. Ritz E, McClellan WM. Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol. 2004;15:513-516.
9. Hallan H, Romundstad S, Kvenild K, et al. Microalbuminuria in diabetic and hypertensive patients and the general population: consequences of various diagnostic criteria: the Nord-Trøndelag Health Study (HUNT). Scand J Urol Nephrol. 2003;37:151-158.
10. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
11. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641-650.
12. McEniery CM. Antihypertensive drugs and central blood pressure. Curr Hypertens Rep. 2009;11:253-259.
13. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis. 2000;36:449-467.
14. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med. 2004;116:263-272.
15. Ichihara A, Sakoda M, Kurauchi-Mito A, Kaneshiro Y, Itoh H. Renin, prorenin and the kidney: a new chapter in an old saga. J Nephrol. 2009;22:306-311.
16. Wolf G. Molecular mechanisms of angiotensin in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant. 1998;13:1131-1143.
17. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int Suppl. 2000;75:S7-S14.
18. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renalbiopsy specimens from patients with persistent glomerular nephritis. Lancet. 1968;2:363-366.
19. Bohle A, von Gise H, Mackensen-Haen S, et al. The obliteration of the postglomerular capillaries and its influence upon the function of both glomeruli and tubuli: functional interpretation of morphologic findings. Klin Wochenschr. 1981;59:1043-1051.
20. Schainuck LI, Striker GE, Cutler RE, et al. Structural-functional correlations in renal disease: Part II: the correlations. Hum Pathol. 1970;1:631-641.
21. Landray MJ, Wheeler DC, Lip GY, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004;43:244-253.
22. Stam F, van Guldener C, Becker A, et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol. 2006;17:537-545.
23. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
24. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906.
25. Rashidi A, Nakhjavani M, Esteghamati A, et al. Association between oxidant/antioxidant markers and proteinuria in type 2 diabetes: results in 142 patients. J Nephrol. 2009;22:733-738.
26. Gambaro G, Kong NC. Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate. J Nephrol. 2010 Feb 1. [Epub ahead of print].
27. Brenner BM. The history and future of renoprotection. Kidney Int. 2003;64:1163-1168.
28. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of an giotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
29. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
30. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
31. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
32. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
33. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672-678.
34. Lacourcière Y, Bélanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58:762-769.
35. Esmatjes E, Flores L, Iñigo P, et al. Effect of losartan on TGFbeta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant. 2001;16(Suppl 1):90-93.
36. Lozano JV, Llisterri JL, Aznar J, et al. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant. 2001;16(Suppl 1):85-89.
37. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672-678.
38. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
39. Guidelines Subcommittee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
40. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-1992.
41. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
42. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(Suppl 1):S1-S290.
43. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs. 2001;61:1501-1529.
44. Stangier J, Su CA, Brickl R, et al. Pharmacokinetics of single dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol. 2000;40:1365-1372.
45. Zou Z, Xi GL, Yuan HB, et al. Telmisartan versus angiotensin converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials. J Hum Hypertens. 2009;23:339-349.
46. Xi GL, Cheng JW, Lu GC. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am J Hypertens. 2008;21:546-552.
47. Delles C, Klingbeil AU, Schneider MP, et al. The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol Dial Transplant. 2004;19:1392-1397.
48. Komers R, Komersova K, Kazdova L, et al. Effect of ACE inhibition and angiotensin AT1 receptor blockade on renal and blood pressure response to L-arginine in humans. J Hypertens. 2000;18:51-59.
49. Svolis KA, Lemboussi DSP, Svolis AA, et al. Telmisartan, an angiotensin II type 1 receptor blocker, improves endothelial function in patients with chronic heart failure [abstract]. J Am Coll Cardiol. 2002;39(Suppl B):266B.
50. Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30:1351-1356.
51. Mimran A, Ribstein J, DuCailar G. Contrasting effect of antihypertensive treatment on the renal response to L-arginine. Hypertension. 1995;26:937-941.
52. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577-1578.
53. Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med. 1996;101(Suppl 3A):22S-32S.
54. Fogari R, Derosa G, Zoppi A, et al. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens. 2007;20:417-422.
55. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-1961.
56. Krutzen E, Back SE, Nilsson-Ehle I, et al. Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med. 1984;104:955-961.
57. Modification of Diet in Renal Disease Study Group. Shortterm effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996;7:2097-2109.
58. Barnett AH. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study. Acta Diabetol. 2005;42:S42-S49.
59. Rossing K, Christensen PK, Hovind P, et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596-1605.
60. Cupisti A, Rizza GM, d'Alessandro C, et al. Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients. Biomed Pharmacother. 2003;57:169-172.
61. Ryšavá R, Tesař V, Merta M. Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease. Blood Press Monit. 2005;10:207-213.
62. Aranda P, Segura J, Ruilope LM, et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis. 2005;46:1074-1079.
63. Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74:364-369.
64. Galle J, Schwedhelm E, Pinnetti S, et al. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 2008;23:3174-3183.
65. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
66. Sharma AM, Hollander A, Köster J. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol. 2005;63:250-257.
67. Cice G, di Benedetto A, d'Isa S, et al. Unexpected heart rate reduction and antihypertensive efficacy of telmisartan in haemodialysis patients. Presented at the 41st congress of the European Renal Association, Lisbon, Portugal, May 15-18, 2004 [abstract SP116].
68. Cice G, di Benedetto A, d'Isa S, et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on mortality and morbidity in haemodialysis patients with chronic heart failure: a double-blind placebo-controlled trial. Nephrol Dial Transplant. 2005;20(Suppl 5):v187 [abstract S034].
69. The ONTARGET Investigators; et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
70. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
71. Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet. 2008;372:511-512.
72. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-1183.